科研之友
微信
新浪微博
Facebook
分享链接
摘要
Background: The efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) remains controversial. Therefore, we conducted a meta-analysis to evaluate the efficacy and safety of sorafenib for treating patients with advanced HCC. @@@ Methods: The PubMed, Embase, and Web of Science databases were searched. Eligible studies were randomized controlled trials (RCTs) that assessed sorafenib therapy in patients with advanced HCC. The outcomes included overall survival (OS), time to progression (TTP), overall response rate (ORR), and toxicities. Hazard ratio (HR) and risk ratio (RR) were used for the meta-analysis and were expressed with 95% confidence intervals (CIs). @@@ Results: Seven RCTs, with a total of 3807 patients, were included in this metaanalysis. All patients received sorafenib alone, or with other chemotherapeutic regimens. Pooled estimates showed that sorafenib improved the OS (HR=0.74, 95% CI: 0.61, 0.90; P=0.002), or TTP outcomes (HR=0.69, 95% CI: 0.55, 0.86; P=0.001). Subgroup analysis revealed that sorafenib was more effective in the patients with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 1-2 (HR=0.77, 95% CI: 0.60, 1.0; P=0.05), or macroscopic vascular invasion (MVI), and/or extrahepatic spread (EHS) (HR=0.65, 95% CI: 0.46, 0.93; P=0.02), in terms of OS. Patients who received sorafenib did not have a higher ORR (RR=0.85, 95% CI: 0.65, 1.11; P=0.10). In addition, there was a slight increase in toxicity in the sorafenib group. @@@ Conclusion: Treatment with sorafenib significantly improved OS and TTP in patients with advanced HCC. Additional large-scale, well-designed RCTs are needed to evaluate the efficacy of sorafenib-based therapy in the treatment of advanced HCC.
- 出版日期2014-12-2
- 单位中国医科大学
